Peter Bronsert

Dr. Peter Bronsert

Institute of Surgical Pathology, Medical Center—University of Freiburg, Breisacher Strasse 115a, 79106 Freiburg, Germany
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Cell
Verified
Journal Article
Open access
BGBarbara T. Grünwald
Barbara T. Grünwald
ADAntoine Devisme
Antoine Devisme
GAGeoffroy Andrieux
Geoffroy Andrieux
FVForam Vyas
Foram Vyas
KAKazeera Aliar
Kazeera Aliar
RKRama Khokha
Rama Khokha
Intratumoral heterogeneity is a critical frontier in understanding how the tumor microenvironment (TME) propels malignant progression. Here, we deconvolute the human pancreatic TME through large-scale integration of histology-guided regional multiOMICs with clinical data and patient-derived preclinical models. We discover "subTMEs," histologically definable tissue states anchored in fibroblast plasticity, with regional relationships to tumor immunity, subtypes, differentiation, and treatment response. "Reactive" subTMEs rich in complex but functionally coordinated fibroblast communities were immune hot and inhabited by aggressive tumor cell phenotypes. The matrix-rich "deserted" subTMEs harbored fewer activated fibroblasts and tumor-suppressive features yet were markedly chemoprotective and enriched upon chemotherapy. SubTMEs originated in fibroblast differentiation trajectories, and transitory states were notable both in single-cell transcriptomics and in situ. The intratumoral co-occurrence of subTMEs produced patient-specific phenotypic and computationally predictable heterogeneity tightly linked to malignant biology. Therefore, heterogeneity within the plentiful, notorious pancreatic TME is not random but marks fundamental tissue organizational units.

18 November 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
EFEmmanouil Fokas
Emmanouil Fokas
ASAnke Schlenska-Lange
Anke Schlenska-Lange
BPBülent Polat
Bülent Polat
GKGunther Klautke
Gunther Klautke
GGGerhard G. Grabenbauer
Gerhard G. Grabenbauer
HFHagen Flach
Hagen Flach
Total neoadjuvant therapy (TNT) is the delivery of chemoradiotherapy (CRT) or short-course radiotherapy (SCRT) and chemotherapy before surgery (or as nonoperative management [NOM]) and has been increasingly adopted for multimodal rectal cancer treatment.1-4 Total neoadjuvant therapy offers several advantages compared with standard CRT/SCRT, surgery, and adjuvant chemotherapy, such as earlier administration of systemic treatment with less toxicity and better compliance, which can decrease distant metastases and improve disease-free survival (DFS). Moreover, TNT (and the longer interval from start of treatment to surgery) may also enhance local tumor regression, pathological complete response (pCR), and R0 (complete) resection rates and may guide patient selection for NOM or local excision. Caveats include the potential overtreatment and unnecessary toxicity of TNT in patients with low- or intermediate-risk rectal cancer and the substantial delay of curative surgery in nonresponding or poorly responding tumors.1-4

19 July 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Jens HoeppnerJens Hoeppner
Jens Hoeppner
FLFlorian Lordick
Florian Lordick
TBThomas Brunner
Thomas Brunner
TGTorben Glatz
Torben Glatz
PBPeter Bronsert
Peter Bronsert
JSJ. Rüdiger Siewert
J. Rüdiger Siewert
Recent randomized controlled trials comparing neoadjuvant chemoradiation plus surgery or perioperative chemotherapy plus surgery with surgery alone showed significant survival benefits for combined modality treatment of patients with localized esophageal adenocarcinoma. However, head-to-head comparisons of neoadjuvant chemoradiation and perioperative chemotherapy applying contemporary treatment protocols are lacking. The present trial was initiated to obtain valid information whether neoadjuvant chemoradiation or perioperative chemotherapy yields better survival in the treatment of localized esophageal adenocarcinoma. The ESOPEC trial is an investigator-initiated multicenter prospective randomized controlled two-arm trial, comparing the efficacy of neoadjuvant chemoradiation (CROSS protocol: 41.4Gy plus carboplatin/paclitaxel) followed by surgery versus perioperative chemotherapy and surgery (FLOT protocol: 5-FU/leucovorin/oxaliplatin/docetaxel) for the curative treatment of localized esophageal adenocarcinoma. Patients with cT1cN + cM0 and cT2-4acNxcM0 esophageal and junctional adenocarcinoma are eligible. The trial aims to include 438 participants who are centrally randomized to one of the two treatment groups in a 1:1 ratio stratified by N-stage and study site. The primary endpoint of the trial is overall survival assessed with a minimum follow-up of 36 months. Secondary objectives are progression-free survival, recurrence-free survival, site of failure, postoperative morbidity and mortality, duration of hospitalization as well as quality of life. The ESOPEC trial compares perioperative chemotherapy according to the FLOT protocol to neoadjuvant chemoradiation according to the CROSS protocol in multimodal treatment of non-metastasized recectable adenocarcinoma of the esophagus and the gastroesophageal junction. The goal of the trial is identify the superior protocol with regard to patient survival, treatment morbidity and quality of life. NCT02509286 (July 22, 2015)

1 July 2021 in Immunity
Verified
Journal Article
Closed access
MSMarius Schwabenland
Marius Schwabenland
HSHenrike Salié
Henrike Salié
JTJovan Tanevski
Jovan Tanevski
SKSaskia Killmer
Saskia Killmer
MLMarilyn Salvat Lago
Marilyn Salvat Lago
BBBertram Bengsch
Bertram Bengsch

23 January 2025 in New England Journal of Medicine
Verified
Journal Article
Closed access
Jens HoeppnerJens Hoeppner
Jens Hoeppner
TBThomas Brunner
Thomas Brunner
CSClaudia Schmoor
Claudia Schmoor
PBPeter Bronsert
Peter Bronsert
BKBirte Kulemann
Birte Kulemann
FLFlorian Lordick
Florian Lordick
The best multimodal approach for resectable locally advanced esophageal adenocarcinoma is unclear. An important question is whether perioperative chemotherapy is preferable to preoperative chemoradiotherapy. In this phase 3, multicenter, randomized trial, we assigned in a 1:1 ratio patients with resectable esophageal adenocarcinoma to receive perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) plus surgery or preoperative chemoradiotherapy (radiotherapy at a dose of 41.4 Gy and carboplatin and paclitaxel) plus surgery. Eligibility criteria included a primary tumor with a clinical stage of cT1 cN+, cT2-4a cN+, or cT2-4a cN0 disease, in which T indicates the size and extent of the tumor (higher numbers indicate a more advanced tumor), and N indicates the presence (N+) or absence (N0) of cancer spread to the lymph nodes, without evidence of metastatic spread. The primary end point was overall survival. From February 2016 through April 2020, we assigned 221 patients to the FLOT group and 217 patients to the preoperative-chemoradiotherapy group. With a median follow-up of 55 months, overall survival at 3 years was 57.4% (95% confidence interval [CI], 50.1 to 64.0) in the FLOT group and 50.7% (95% CI, 43.5 to 57.5) in the preoperative-chemoradiotherapy group (hazard ratio for death, 0.70; 95% CI, 0.53 to 0.92; P = 0.01). Progression-free survival at 3 years was 51.6% (95% CI, 44.3 to 58.4) in the FLOT group and 35.0% (95% CI, 28.4 to 41.7) in the preoperative-chemoradiotherapy group (hazard ratio for disease progression or death, 0.66; 95% CI, 0.51 to 0.85). Among the patients who started the assigned treatment, grade 3 or higher adverse events were observed in 120 of 207 patients (58.0%) in the FLOT group and in 98 of 196 patients (50.0%) in the preoperative-chemoradiotherapy group. Serious adverse events were observed in 98 of 207 patients (47.3%) in the FLOT group and in 82 of 196 patients (41.8%) in the preoperative-chemoradiotherapy group. Mortality at 90 days after surgery was 3.1% in the FLOT group and 5.6% in the preoperative-chemoradiotherapy group. Perioperative chemotherapy with FLOT led to improved survival among patients with resectable esophageal adenocarcinoma as compared with preoperative chemoradiotherapy. (Funded by the German Research Foundation; ESOPEC ClinicalTrials.gov number, NCT02509286.).

1 August 2014 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
PBPeter Bronsert
Peter Bronsert
KEK Enderle‐Ammour
K Enderle‐Ammour
MBM Bader
M Bader
STS Timme
S Timme
MKM Kuehs
M Kuehs
Ulrich Friedrich WellnerUlrich Friedrich Wellner
Ulrich Friedrich Wellner